ELElena Alekseevna Lukina

Elena Alekseevna Lukina

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Elena Alekseevna Lukina has a total of 341 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Pattern of T-Lymphocyte Subpopulation in Patients with Cold Agglutinin Disease

    by Polina Igorevna Vasilchenkova, M. N. Finyakina, O. F. Nikulina, N. V. Tsvetaeva, S. M. Kulikov, I. V. Galtseva, E. A. Lukina

    BACKGROUND. Cold agglutinin disease (CAD) is an orphan hematologic disease characterized mainly by hemolytic anemia, increased titer of cold antibodies, and clonality of B-lymphocytes in peripheral blood or/and bone marrow. The role of T-cell population imbalance in CAD has not been studied due to the rarity of this disease and extreme heterogeneity of its clinical and laboratory manifestations. AIM. To analyze the pattern of T-lymphocyte subpopulation in CAD patients and to assess the information value of immune parameters for predicting the treatment efficacy and relapse risk. MATERIALS & METHODS. Over the period from 2020 to 2023, 128 patients with autoimmune hemolytic anemia were examined and treated at the National Research Center for Hematology, the CAD diagnosis was confirmed in 25 of them. The control group consisted of 57 healthy blood donors. RESULTS. Primary CAD patients showed significant decrease of naïve and central memory T-cells compared to similar subpopulations in donors. In 3 and 6 months after completion of immunosuppressive therapy with rituximab, CAD patients had a significant increase of T-helpers and cytotoxic T-lymphocytes as well as a decrease of T-regulatory cells. Among T-helper subpopulations, an increase in Th2 and Th17 cells was reported. The patients who achieved complete hematologic response prior to rituximab therapy, demonstrated a significant increase in Th22 cells. After 3 months of treatment, non-responders showed a drastic increase in cytotoxic T-lymphocytes followed by a decrease to baseline. CONCLUSION. The analysis of the phenotypic spectrum of T-cells demonstrated the difference between the count of naïve and central memory T-cells in CAD patients and healthy donors. This study revealed no significant association of these parameters with the response to immunosuppressive therapy. The only factor associated with achieving complete hematologic response to rituximab was a higher Th22 baseline level compared to donor population.

  • Experience with pegcetacoplan in patients with paroxysmal nocturnal hemoglobinuria and suboptimal response to C5 inhibitor therapy

    by Maria N. Finyakina, Финякина Мария Николаевна, O. F. Nikulina, Никулина О. Ф., I. V. Galtseva, Гальцева И. В., I. I. Mulina, Мулина И. И., Z. A. Ochirova, Очирова З. А., et al.

    Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired clonal hematologic disorder whose pathogenesis is primarily driven by the formation of a cell clone (the PNH clone) lacking surface protective glycoproteins (CD55 and CD59), activation of the alternative complement pathway, and complement-mediated destruction of erythrocytes within blood vessels (intravascular hemolysis). This process underlies the main clinical manifestations of PNH – hemolytic anemia and thrombotic complications. The introduction of eculizumab, a C5 complement inhibitor, into clinical practice in 2007, which blocks the mechanism of intravascular hemolysis, revolutionized the course and prognosis of PNH. However, 30–45 % of patients continue to experience anemia and require replacement blood transfusions after 6 months or more of regular C5 inhibitor therapy. It has been established that the most common cause of a suboptimal treatment response is extravascular hemolysis, which is based on opsonization of PNH erythrocytes by C3b complement fragments followed by phagocytosis and degradation of these cells by macrophages in the liver and spleen. To suppress the mechanism of extravascular hemolysis, inhibitors of the proximal complement pathway have been developed, including the C3 inhibitor pegcetacoplan, which was registered in Russia in 2023 under the trade name Empaveli. The drug inhibits the activity of C3 and C3b complement components and thereby blocks the entire complement activation cascade, providing suppression of both intravascular and extravascular hemolysis. This article presents the first Russian experience of treating nine PNH patients with suboptimal response to C5 inhibitor therapy with pegcetacoplan. All nine patients demonstrated an average increase in hemoglobin levels of 25 g / L from baseline, achieving transfusion independence. The article also provides a detailed description of three clinical cases of particular interest.

  • Open Access

    Substrate reduction therapy with eliglustat in patients with Gaucher disease type 1

    by M. T. Galimova, E. A. Lukina

    Currently, there are two approaches to treating hereditary enzyme deficiency – Gaucher disease: intravenous infusions of recombinant enzyme – imiglucerase, velaglucerase, or taliglucerase (enzyme replacement therapy), and substrate reduction therapy with eliglustat, the advantage of which is oral administration 1–2 times a day. International phase II/III clinical trials conducted between 2006 and 2016 demonstrated high efficacy and safety of eliglustat for adult patients with Gaucher disease type 1 without severe comorbidities. According to the results of these studies, eliglustat was approved for the treatment of Gaucher disease in the United States and the European Union in 2014. A multicenter study evaluating the efficacy and safety of eliglustat in children with Gaucher disease was initiated in 2018 and completed in December 2025. This literature review summarizes data on the mechanism of action of eliglustat, its dosing characteristics, and its potential use in patients with concomitant organ pathology. In addition, the results of a comparison of changes in Gaucher disease biomarkers during substrate reduction therapy with eliglustat and enzyme replacement therapy are presented.

  • Open Access

    Interim results of the first stage of a multicenter open multi-cohort study of the safety, pharmacokinetics, pharmacodynamics and efficacy of veranafusp alfa in adult patients with mucopolysaccharidosis type II

    by E. A. Lukina, R. V. Ponomarev, S. V. Trishina, E. S. Gabitova, N. D. Vashakmadze, G. A. Karkashadze, L. S. Namazova-Baranova

    This article presents the interim results of the first stage (administration of the drug to patients aged ≥18 years with mucopolysaccharidosis type II) of a multicenter open multi-cohort phase II-III study (IDB-MPS-II-III), the aim of which was to assess the safety, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of veranafusp alfa in patients with MPS II. Material and methods. The interim analysis included data from 3 patients aged 18 years and older who had previously received idursulfase (2/3) and idursulfase beta (1/3). An individual dose increase (1–2–3 mg/kg) was performed after 2 weeks, followed by administration at a dose of 3 mg/kg for up to 52 weeks (a total of 52 weekly infusions). Standard PK parameters were evaluated. The PD criterion was the level of glycosaminoglycans (GAGs) in urine, blood and cerebrospinal fluid (CSF). Efficacy parameters included assessment of the dynamics of GAGs concentration in urine, blood and CSF, range of motion in joints, liver and spleen volume, change in the 6-minute walk test (6MWT, 6-minute test), left ventricular myocardial mass, forced vital capacity of the lungs (FVC). Safety parameters included assessment of the frequency of adverse events (AEs) and adverse reactions (ARs), including allergic and infusion reactions, as well as assessment of the frequency of formation of anti-drug antibodies (ADAs) and their neutralizing activity. Results. The studied drug demonstrated non-linear PK in the blood and a dose-dependent increase in concentration in the CSF. Patients showed a decrease or stability in the level of GAG in the urine, a decrease in the level of heparan sulfate (HS) in the CSF in 2 (66.6%) of 3 patients, as well as a decrease in the level of dermatan sulfate (DS) in the CSF in the range of 17.19–80.96%. There was an average decrease in liver volume by 42.500 ± 218.496 cm 3 , spleen volume by 24.350 ± 9.405 cm 3 and left ventricular myocardial mass by 15.333 ± 43.016 g relative to the baseline level. The average increase in walking distance according to the results of the 6MWT, after 1 year of therapy, was 76.067 ± 83.561 m. The average values of FVC and FEV1 did not change statistically significantly. 9 AEs were registered in 3 patients (100.0%) of mild severity, mainly from the liver and biliary tract, and 3 ARs, which were infusion reactions and were registered mainly in the first 4 months of therapy. During the analyzed period, the frequency of formation of ADAs at screening was in 2 patients, and at week 52 — in 3 patients, which indicates the development of de novo ADAs during treatment with veranafusp alfa in 1 patient. Conclusion. Weekly intravenous administration of the drug under study to adult patients at a dose of 3 mg/kg for 1 year provided control of the level of GAG in the urine and stabilization and/or improvement of somatic symptoms according to spirometry, echocardiography, 6MWT, range of motion in large joints, liver and spleen size, comparable to the results of the effectiveness of treatment with idursulfase in patients previously receiving enzyme replacement therapy. There was a tendency to decrease the level of HS in the cerebrospinal fluid, which may indicate the ability of veranafusp alfa to penetrate the BBB and deliver idursulfase to brain tissue, preventing the accumulation of pathological substrate in the CNS to prevent neurodegenerative changes.


  • Open Access

    Management of patients with iron deficiency anemia in the context of primary health care. Guidelines

    by O. M. Drapkina, E. B. Avalueva, I. G. Bakulin, B. А. Bakirov, I. I. Baranov, N. G. Vinogradova, M. A. Vinogradova, T. V. Gaponova, O. V. Gaus, S. R. Gilyarevsky, et al.

    Iron deficiency anemia is a multietiological disease, the development of which is associated with iron deficiency due to its impaired intake, absorption or increased losses, characterized by microcytosis and hypochromic anemia. The practical guide describes in detail the etiology, paraclinical diagnostics, management of patients in various clinical situations. Guidelines are intended for primary health care professionals, including internists, general practitioners, cardiologists, gastroenterologists and other specialists providing care to patients with iron deficiency anemia.


  • Open Access

    Total hip arthroplasty in patients with Gaucher disease: characteristics and outcomes

    by Vasily E. Mamonov, Yulya A. Chabaeva, Vladimir A. Khomenko, Rodion V. Ponomarev, Elena A. Lukina

    BACKGROUND: Avascular necrosis of the femoral head (ANFH) is the indication for total hip arthroplasty (THA) in patients with Gaucher disease (GD). Due to the rarity of GD, the surgical procedure and long-term outcomes in large patient populations have been insufficiently studied. AIM: This study aimed to analyze the perioperative period as well as medium- and long-term outcomes of THA in patients with GD. METHODS: A retrospective, single-center study was conducted in 26 patients with GD who underwent 30 primary THAs and 9 revision hip arthroplasties between 2005 and 2023. RESULTS: Good and excellent THA outcomes were achieved in 87% of cases, with follow-up periods ranging from 1 to 10 years (median: 7 years). Unsatisfactory results during the 10-year follow-up were due to periprosthetic infection (2 cases) and aseptic loosening (3 cases). Both cases of periprosthetic infection were caused by osteoarticular tuberculosis, which was not detected at the prehospital stage. High intraoperative blood loss was associated with the duration of enzyme replacement therapy (ERT). Blood loss of 1000 mL was reported in 57%, 22%, and 0% of surgeries when ERT lasted less than 5 years, 5–10 years, and more than 10 years, respectively (p = 0.047). Implant survival without revision 3, 6, and 12 years post-surgery was 97%, 93%, and 61%, respectively. At 12 years, the survival rates for cemented and uncemented implants without revision were 33% and 67%, respectively. Twelve years post-surgery, implant survival without revision was 43% for the CoCr/PE bearing surface and 83% for other combinations (ceramic/ceramic, ceramic/PE, and modified metal / PE). CONCLUSION: THA improves quality of life in patients with GD after ANFH. Uncemented implants with ceramic-on-ceramic, ceramic-on-polyethylene, or modified metal-on-polyethylene bearings demonstrated greater longevity and lower revision rates. A high risk of perioperative hemorrhagic complications was observed in patients who received ERT for less than 5 years. The risk of periprosthetic infection was 6.7%, and tuberculosis should be ruled out in such cases.


  • Open Access

    Sociomedical Profile and Quality of Life of Paroxysmal Nocturnal Hemoglobinuria Patients with Suboptimal Response to Pathogenetic Therapy

    by T. I. Ionova, A. D. Kulagin, E. A. Lukina, V. V. Ptushkin, E. G. Arshanskaya, T. N. Babaeva, B. A. Bakirov, S. V. Voloshin, G. P. Dimov, O. U. Klimova, et al.

    BACKGROUND. Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired clonal non-neoplastic disorder of hematopoietic tissue characterized by complement-mediated hemolysis, bone marrow dysfunction, and higher risk of thrombotic and organic complications. This disease is associated with rapid rate of progression as well as worsening life expectancy and quality of life. Despite high efficacy of anti-complement treatment, a considerable proportion of patients show suboptimal response to pathogenetic therapy. Problems that patients encounter in everyday life, their quality of life, burden of disease, and limitations in professional life have not been adequately addressed in literature. AIM. To study sociomedical profile and quality-of-life indicators of PNH patients with suboptimal response to pathogenetic therapy and to assess the FACIT-Fatigue Scale in terms of its clinical information value and practical significance for analyzing the overall treatment success. MATERIALS & METHODS. As part of the multicenter observational clinical study, PNH patients with suboptimal response to pathogenetic therapy completed the EQ-5D and FACIT-Fatigue questionnaires as well as a checklist of main PNH symptoms, their disease, treatment, and professional life. The method of descriptive statistics as well as the Mann-Whitney test, the χ2 test, and correlation analysis were used to analyze the data. RESULTS. The study was based on the data from 45 PNH patients treated in 12 health centers in Russia (classic PNH accounted for 64.4 %). The age median was 41 years, 62 % of patients were women. The mean duration of suboptimal response to pathogenetic therapy was 3.2 years. Most patients had mobility issues (55.6 %), anxiety/depression (62.2 %), and hardships in their daily activities (68.9 %). In the vast majority of them, the disease had a moderate or considerable impact on their daily activities and social/family life. In 61 % of professionally active patients, the underlying disease moderately or considerably limited their professional life. Most patients reported fatigue (96 %), headache (86 %), dyspnea (83 %), concentration issues and sleep disorders (82 %), rapid heartbeat (77 %), yellowness of the skin (76 %), and back pain (71 %). Pronounced fatigue (with FACIT-Fatigue score of < 40) was registered in 70 % of patients. A significant correlation was established between FACIT-Fatigue and EQ-5D VAS scores as well as a relationship with the severity of dyspnea, tachycardia, and concentration loss. CONCLUSION. This clinical study demonstrated a considerably reduced quality of life of PNH patients with suboptimal response to pathogenetic therapy. It also confirmed the information value of the FACIT-Fatigue Scale for assessing fatigue and its impact on everyday life. This study clearly identified outstanding issues related to PNH patients with suboptimal response to pathogenetic therapy. That can contribute to bringing more patient-oriented care to this challenging population of hematologic patients.


  • Open Access

    Esophagogastric Bleedings in Patients with Ph-Negative Myeloproliferative Neoplasms and Extrahepatic Portal Hypertension

    by Pavel Artemovich Batrov, K. I. Danishian, E. P. Sysoeva, K. R. Sabirov, O. M. Averbukh, O. A. Soboleva, E.A. Kitsenko Kitsenko, E. A. Lukina

    AIM. To assess the treatment outcomes in esophagogastric bleeding patients with Ph-negative myeloproliferative neoplasms (MPN) and extrahepatic portal hypertension caused by thrombotic complications. MATERIALS & METHODS. The present prospective clinical trial performed in the surgical department of the National Research Center for Hematology from 2013 to 2024 enrolled 52 patients with Ph-negative MPNs and extrahepatic portal hypertension caused by total portal vein thrombosis. The median age of patients was 45 years (range 25–68 years). Young (≤ 40 years) and middle-aged (≤ 60 years) patients predominated: 16 (30.8 %) and 31 (59.6 %), respectively. There were 5 (9.6 %) elderly (> 60 years) patients. The V617F mutation in JAK2 was detected in 41 (78.8 %) out of 52 patients. RESULTS. Splenectomy was performed in 49 patients, 41 (78.8 %) out of them also underwent gastrotomy as well as esophageal/gastric variceal ligation. Gastrotomy was not carried out in 10 (19.2 %) out of 52 patients. Laparotomy with gastrotomy along with esophageal and gastric variceal ligation (without splenectomy) was performed in 3 (5.8 %) patients. Repeated bleedings were registered in 2 of them, which required further splenectomy. Overall incidence of postoperative complications was 21 %. Long-term rebleedings reported in 7 (13.5 %) patients were treated non-surgically. The 5-year overall survival in the total group (n = 52) was 90.1 %. At later stages of Ph-negative MPNs, 5 (9.6 %) deaths were registered as a result of the blast transformation of the disease (n = 3) and thrombohemorrhagic complications (n = 2). CONCLUSION. Patients with Ph-negative MPNs and extrahepatic portal hypertension caused by portal vein thrombosis represent most complicated cases. However, surgical procedures, such as splenectomy combined with gastrotomy and esophageal/gastric variceal ligation, considerably improve long-term treatment outcomes despite a relatively high incidence of postoperative complications (thrombotic, hemorrhagic, purulent, and inflammatory ones).


  • Open Access

    Results of a prospective observational study of imiglucerase biosimilar in adults with type I Gaucher disease

    by E A Lukina, R V Ponomarev, G N Salogub, V A Bezrukikh, E V Saifullina, I L Davydkin, S A Volkova, T V Shelekhova, M V Kosinova, E V Vasiliev, et al.

    Aim. To collect and analyze real-world data on long-term enzyme replacement therapy with Glurazyme® in patients with type I Gaucher disease (GD). Materials and methods. The study included 31 patients with type I GD (21 patients with intact spleen and 10 patients with a history of splenectomy) over 18 years. Efficacy was assessed by the change in hemoglobin level (primary endpoint), platelet count, spleen and liver volumes, prevalence of bone marrow infiltration, and the number of patients with quiet hip disease according to magnetic resonance imaging (secondary endpoints). Safety was assessed by the incidence of treatment-related adverse events and serious adverse events, as well as by the incidence of production of imiglucerase binding and neutralizing antibodies (IgG, IgE). The mean follow-up duration was 54 weeks. Results. The study did not show a statistically significant change in hemoglobin levels, platelet count, or spleen and liver volumes. There was an upward tendency in platelet count in the overall group (p=0.1) and patients after splenectomy (p=0.08). The prevalence of specific bone marrow infiltration and the number of patients with quiet hip disease remained unchanged. During the safety analysis, one adverse reaction, a mild increase in alanine aminotransferase, was reported, which resolved spontaneously by the end of the study. The immunogenicity analysis showed the initial presence of anti-drug antibodies (ADAs) in 5 (16.7%) of the 30 examined patients. At the end of the study, ADAs were detected in only 3 (10%) patients. The detected ADAs had a low titer and no neutralizing activity, and they did not affect the treatment effectiveness. Conclusion. Long-term therapy with the imiglucerase biosimilar was associated with a stable course of GD without progression. It was characterized by a good safety profile and low immunogenicity.


  • Open Access

    Radiological and morphological characteristics of the femoral head osteonecrosis in type I Gaucher disease

    by Vasily E. Mamonov, Anastasia A. Solovyova, Dmitry I. Chebotarev, Rodion V. Ponomarev, Vladislav A. Nakonechny, Elena A. Lukina, Соловьева Анастасия Александровна

    BACKGROUND: Osteonecrosis of the femoral head in Gaucher disease type I is an irreversible bone manifestation of the disease. The cause and mechanisms of osteonecrosis in Gaucher disease are still unknown, and their clinical and radiological characteristics must be taken into account when choosing treatment strategy. AIM: To analyze the radial and morphological changes in the proximal femur after osteonecrosis of the femoral head in type I Gaucher disease. MATERIALS AND METHODS: The study included 251 adult patients with type I Gaucher disease from the Russian National Registry; histological examination of 22 removed femoral bone fragments obtained during total hip replacement in 20 patients with Gaucher disease and 9 in patients of the control group was performed. RESULTS: Aseptic necrosis of the femoral head was found in 30% adults with Gaucher disease, and in 20% patients it was associated with femoral head collapse. Osteosclerosis of the cancellous bone of the metaphysis, enlargement / swelling of the medullary cavity with secondary osteopenia and osteoporosis of the proximal femoral diaphysis often accompanied osteonecrosis of the femoral head, causing technical difficulties during surgery. The histological findings revealed a picture of chronic bone tissue ischaemia of the proximal femoral metaphysis, which was confirmed by the detection of widespread areas of osteosclerosis on radiography and MRI. Bone marrow infiltration by Gaucher cells in histological preparations persisted regardless of the duration of enzyme replacement therapy against the background of preserved regenerative potential of bone tissue. CONCLUSIONS: The features of the radiological, MRI and histological picture should be taken into account when planning and performing orthopaedic surgery for aseptic necrosis of the femoral head in patients with type I Gaucher disease.